Oral Drug Delivery Videos

  1. Oral Peptide Delivery with Protagonist Therapeutics' Dinesh Patel 8/22/2024

    To stab or to swallow? For treating conditions in the I&I (immunology and inflammation) space – think psoriasis, as one common example – some see the holy grail of delivery as moving from injectable to oral administration. In this inaugural episode of Sit and Deliver, host Tom von Gunden invites Dinesh Patel, president and CEO at clinical stage biotech company Protagonist Therapeutics, to deliver the rationale for targeting I&I diseases and other therapeutic areas with oral peptides.

  2. Expanding Biologics Delivery Options Via Oral Devices With Biograil's Karsten Lindhardt 4/25/2025

    Large, complex molecules present significant challenges in the formulation and absorption of biologics-based therapies administered orally. In this episode of Supplier Horizons, host Tom von Gunden talks with CEO Karsten Lindhardt of oral platform technology developer Biograil about capsule-enclosed combination devices that offer patients convenience, safety, and effectiveness while bolstering patient compliance.

  3. Patient Safety Through Overdose Protection With Elysium Therapeutics' Greg Sturmer 11/18/2024

    Drug overdoses can result both from knowingly risky behavior, such as opioid use disorder, and from unwitting patient acts of over-consumption. In this episode of Sit and Deliver, Greg Sturmer, co-founder and CEO of biopharmaceutical company Elysium Therapeutics, talks with Sit and Deliver host Tom von Gunden about ways to add overdose inhibitors to oral medications prone to abuse or misuse.

  4. Leveraging Combination Therapies For Precision Targeting 10/8/2025

    In this segment of the Drug Delivery Leader Live online event, Next-Gen Drug Delivery: Rethinking Routes For New Therapies, Carolyn Dorgan, director of technical services at device design consultancy Suttons Creek, highlights the promise of using combination products and combination therapies to reach difficult targets with precision. Carolyn notes crossing the blood-brain barrier as an example of a key therapy delivery advance. 

  5. Partnership And Clinical Trial Strategies For Digitally Connected Devices 5/23/2025

    In this segment of the Drug Delivery Leader Live online event, Innovations In Drug Delivery: Opportunities For Enhancing Familiar, Mature Approaches, James Wabby, head of global regulatory affairs for emerging device technologies and combination products at AbbVie, and Carolyn Dorgan, director of technical services at device design consultancy Suttons Creek, discuss key product development considerations when bringing digital connectivity solutions to drug delivery devices. These aspects include product and health authority partnerships, clinical studies, and regulatory approvals.

  6. Taste Masking 101: Sensory And Performance Evaluation 7/11/2022

    Learn how techniques and innovations in taste masking sensory and performance evaluation can help accelerate your formulation development and confirm desired taste profile.

  7. What's In A Combination Product Development Lifecycle? 10/8/2025

    In this segment of the Drug Delivery Leader Live online event, Next-Gen Drug Delivery: Rethinking Routes For New Therapies, Carolyn Dorgan, director of technical services at device design consultancy Suttons Creek, lays out the phases and key activities in the development of a combination product or combination therapy. She underscores the importance of integrated development when merging medicinal product development with delivery device development. 

  8. Improve The Performance Of Your Small And Large Molecule Medicines 7/23/2024

    Explore the latest in nanotechnology advancements including recent clinical data, formulation applications, and API optimization to NanoImprove formulations.

  9. The Role Of Combination Products In Combatting Chronic Diseases 1/12/2026

    In this segment of the Drug Delivery Leader Live online event, Eying The Drug Delivery Regulatory Landscape: The 'Must See' Watch List For 2026, Chief Editor Tom von Gunden asks the panel to comment on front-of-mind regulatory movements of note. From her role as Director of Regulatory Policy at Novo Nordisk, Rumi Young identifies the inclusion of combination products in FDA initiatives focused on combatting chronic diseases and improving patient accessibility. Panelists Barr Weiner and Fran DeGrazio weigh in.

  10. Minitabs Technology 8/29/2024

    Discover a multiparticulate system that provides unparalleled flexibility in dosage forms, which allows you to create customized release profiles, precise dosing, and a wide range of delivery options.